{"id":"W4404171664","doi":"10.1016/j.jaci.2024.10.031","title":"Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis","year":2024,"lang":"en","type":"article","venue":"Journal of Allergy and Clinical Immunology","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Atopic dermatitis; Medicine; Randomized controlled trial; Dermatology; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002532126,0.002148704,0.002610571,0.0004441002,0.0004897288,0.001113049,0.0008625042,0.002004605,0.009963277],"category_scores_gemma":[0.002036092,0.0008280855,0.001008802,0.0003224131,0.0009120543,0.001185812,0.0004819064,0.002527102,0.001427431],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007579019,"about_ca_system_score_gemma":0.001476673,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005951637,"about_ca_topic_score_gemma":0.00174471,"domain_scores_codex":[0.9993297,0.0003595163,0.00003295835,0.0001294275,0.00005702746,0.00009137285],"domain_scores_gemma":[0.999193,0.0002023309,0.0001859279,0.00006626784,0.00007299647,0.0002794609],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.963584,0.0159383,0.0009976508,0.0004810931,0.0004614366,0.00006141593,0.000062241,0.0002893155,0.003769455,0.0001369192,0.001936493,0.0122818],"study_design_scores_gemma":[0.9665422,0.0312142,0.001026546,0.00001307605,0.00008712963,0.00002910317,0.0000075909,0.0002177883,0.0001606478,0.00007598088,0.0006195033,0.000006355622],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9679762,0.004630729,0.001099465,0.001580174,0.0008108683,0.01725088,0.002768665,0.0002280323,0.00365499],"genre_scores_gemma":[0.9553943,0.002795033,0.003740295,0.003131501,0.0009929535,0.02381691,0.003121995,0.00004699272,0.006960053],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009963277,"threshold_uncertainty_score":0.0333305,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02306076361483318,"score_gpt":0.3762451066838481,"score_spread":0.353184343069015,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}